Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

作者：Caicun Zhou, Ziping Wang, Meili Sun, Lejie Cao, Zhiyong Ma, Rong Wu, Yan Yu, Wenxiu Yao, Si Sun, Jianhua Chen, Wu Zhuang, Jiuwei Cui, Xueqin Chen, You Lü, Hong Shen, Chunhong Hu, Jiwei Liu, Yunpeng Liu, Mengzhao Wang, Xingya Li, Ping Sun, Yongqian Shu, Jianying Zhou, Jingzhang Li, Kangsheng Gu, Changli Wang, Hui Zhao, Yiping Zhang, Chunling Liu, Jingru Wang, Rumei Chen, Mengmeng Qin, Hao Wang, Jason Yang · 发表于：Nature Cancer · 年份：2023 · DOI：10.1038/s43018-023-00578-z · 被引用次数：35 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Research Studies、Cancer Immunotherapy and Biomarkers